Literature DB >> 16528457

Destruction of human retinoblastoma after treatment by the E variant of encephalomyocarditis virus.

Masazumi Adachi1, Steven E Brooks, Maxine R Stein, Bernice E Franklin, Francis A Caccavo.   

Abstract

The oncolytic effects of encephalomyocarditis (EMC) virus were examined in human retinoblastoma cell (Y79) cultures which were infected with 10(4 )tissue culture infectious doses (TCIDs) of the E variant of EMC (EMC-E) virus. The TCIDs were used to titer the maximum effect of EMC virus on L-929 cells. In-vitro studies showed 90% cytopathic effect (CPE) at 24 h and 100% CPE at 52 h. The CPE was used to observe pathologic effects of the cells. In-vivo studies employing human retinoblastoma grown as a tumor in nude mice, revealed degeneration of 80% of the tumor cells at 3 days and total destruction at 4 days following inoculation with the EMC-E virus. The virus is highly neurotropic in mice, but is usually not pathogenic in man. These studies suggest a possible new direction in the treatment of retinoblastoma and other malignant tumors using the viral technology.

Entities:  

Mesh:

Year:  2006        PMID: 16528457     DOI: 10.1007/s11060-005-9036-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  PREPARATIVE ELECTROPHORESIS OF PROTEINS IN ACRYLAMIDE GELS.

Authors:  J V MAIZEL
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

2.  Central nervous system syndromes of "vital" etiology. A study of 713 cases.

Authors:  H M MEYER; R T JOHNSON; I P CRAWFORD; H E DASCOMB; N G ROGERS
Journal:  Am J Med       Date:  1960-08       Impact factor: 4.965

3.  Ultrastructural alterations of tissue cultures from human fetal brain infected with the E variant of EMC virus.

Authors:  M Adachi; D Amsterdam; S E Brooks; B W Volk
Journal:  Acta Neuropathol       Date:  1975-08-11       Impact factor: 17.088

4.  A structural model for picornaviruses as suggested from an analysis of urea-degraded virions and procapsids of coxsackievirus B3.

Authors:  L Philipson; S T Beatrice; R L Crowell
Journal:  Virology       Date:  1973-07       Impact factor: 3.616

5.  Cytogenetic analysis of retinoblastoma: evidence for multifocal origin and in vivo gene amplification.

Authors:  E Chaum; R M Ellsworth; D H Abramson; B G Haik; F D Kitchin; R S Chaganti
Journal:  Cytogenet Cell Genet       Date:  1984

6.  Location of the retinoblastoma susceptibility gene(s) and the human esterase D locus.

Authors:  P Ward; S Packman; W Loughman; M Sparkes; R Sparkes; A McMahon; T Gregory; A Ablin
Journal:  J Med Genet       Date:  1984-04       Impact factor: 6.318

7.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

8.  Mouse chromosome 5 codes for ecotropic murine leukaemia virus cell-surface receptor.

Authors:  H K Oie; A F Gazdar; P A Lalley; E K Russell; J D Minna; J DeLarco; G J Todaro; U Francke
Journal:  Nature       Date:  1978-07-06       Impact factor: 49.962

9.  The mammalian cell-virus relationship. I. Attachment of poliovirus to cultivated cells of primate and non-primate origin.

Authors:  L C McLAREN; J J HOLLAND; J T SYVERTON
Journal:  J Exp Med       Date:  1959-05-01       Impact factor: 14.307

10.  Virus-induced diabetes mellitus. XVIII. Inhibition by a nondiabetogenic variant of encephalomyocarditis virus.

Authors:  J W Yoon; P R McClintock; T Onodera; A L Notkins
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  2 in total

1.  An optimized gene transfection system in WERI-Rb1 cells.

Authors:  Ying Liu; Zhigang Fan; Kang Li; Fei Deng; Yunfan Xiong; Meixin Liang; Jian Ge
Journal:  Int J Mol Med       Date:  2017-07-06       Impact factor: 4.101

Review 2.  Developing Picornaviruses for Cancer Therapy.

Authors:  Cormac McCarthy; Nadishka Jayawardena; Laura N Burga; Mihnea Bostina
Journal:  Cancers (Basel)       Date:  2019-05-16       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.